175 related articles for article (PubMed ID: 23372647)
1. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric.
Neal ML; Trister AD; Cloke T; Sodt R; Ahn S; Baldock AL; Bridge CA; Lai A; Cloughesy TF; Mrugala MM; Rockhill JK; Rockne RC; Swanson KR
PLoS One; 2013; 8(1):e51951. PubMed ID: 23372647
[TBL] [Abstract][Full Text] [Related]
2. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.
Neal ML; Trister AD; Ahn S; Baldock A; Bridge CA; Guyman L; Lange J; Sodt R; Cloke T; Lai A; Cloughesy TF; Mrugala MM; Rockhill JK; Rockne RC; Swanson KR
Cancer Res; 2013 May; 73(10):2976-86. PubMed ID: 23400596
[TBL] [Abstract][Full Text] [Related]
3. CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage.
Liu WH; Lin JC; Chou YC; Li MH; Tsai JT
Cancer Med; 2020 Jan; 9(1):350-360. PubMed ID: 31746135
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
5. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
Rahman R; Trippa L; Alden S; Fell G; Abbasi T; Mundkur Y; Singh NK; Talawdekar A; Husain Z; Vali S; Ligon KL; Wen PY; Alexander BM
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):716-724. PubMed ID: 32417407
[TBL] [Abstract][Full Text] [Related]
7. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
9. GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival.
Lee CH; Alpert BO; Sankaranarayanan P; Alter O
PLoS One; 2012; 7(1):e30098. PubMed ID: 22291905
[TBL] [Abstract][Full Text] [Related]
10. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
[TBL] [Abstract][Full Text] [Related]
11. Comparison of time taken from initial presentation to histological diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United Kingdom and Strasbourg, France.
Natalwala A; Bharkhada V; Noel G; Cruickshank G
Clin Neurol Neurosurg; 2011 Jun; 113(5):358-61. PubMed ID: 21470768
[TBL] [Abstract][Full Text] [Related]
12. Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation: laboratory investigation.
Sheehan J; Ionescu A; Pouratian N; Hamilton DK; Schlesinger D; Oskouian RJ; Sansur C
J Neurosurg; 2008 May; 108(5):972-8. PubMed ID: 18447715
[TBL] [Abstract][Full Text] [Related]
13. Quantifying Uncertainty and Robustness in a Biomathematical Model-Based Patient-Specific Response Metric for Glioblastoma.
Hawkins-Daarud A; Johnston SK; Swanson KR
JCO Clin Cancer Inform; 2019 Feb; 3():1-8. PubMed ID: 30758984
[TBL] [Abstract][Full Text] [Related]
14. Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy.
Duma CM; Kim BS; Chen PV; Plunkett ME; Mackintosh R; Mathews MS; Casserly RM; Mendez GA; Furman DJ; Smith G; Oh N; Caraway CA; Sanathara AR; Dillman RO; Riley AS; Weiland D; Stemler L; Cannell R; Abrams DA; Smith A; Owen CM; Eisenberg B; Brant-Zawadzki M
J Neurosurg; 2016 Dec; 125(Suppl 1):40-49. PubMed ID: 27903197
[TBL] [Abstract][Full Text] [Related]
15. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
16. Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients.
Peeken JC; Hesse J; Haller B; Kessel KA; Nüsslin F; Combs SE
Strahlenther Onkol; 2018 Jun; 194(6):580-590. PubMed ID: 29442128
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma.
Yang D; Rao G; Martinez J; Veeraraghavan A; Rao A
Med Phys; 2015 Nov; 42(11):6725-35. PubMed ID: 26520762
[TBL] [Abstract][Full Text] [Related]
18. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
19. Treatment and survival of patients harboring histological variants of glioblastoma.
Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
[TBL] [Abstract][Full Text] [Related]
20. Identifying spatial imaging biomarkers of glioblastoma multiforme for survival group prediction.
Zhou M; Chaudhury B; Hall LO; Goldgof DB; Gillies RJ; Gatenby RA
J Magn Reson Imaging; 2017 Jul; 46(1):115-123. PubMed ID: 27678245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
